What's Happening?
Bruntwood SciTech has announced a significant lease agreement with Cellular Origins for the Da Vinci Building at Melbourn Science Park in Cambridge. Cellular Origins, a leader in automated cell therapy manufacturing, will establish its new global headquarters
at the site, which was previously occupied by AstraZeneca. The expanded headquarters will support the development and deployment of Cellular Origins' automated manufacturing platform, Constellation, and the delivery of commercial-scale cell therapy systems. The move will allow for significant expansion plans, including doubling the workforce and enhancing collaboration with global partners like Johnson & Johnson. Cellular Origins aims to industrialize cell therapy manufacturing at scale by combining robotics, automation, and AI with proven bioprocess technologies.
Why It's Important?
The agreement between Bruntwood SciTech and Cellular Origins is crucial for advancing cell therapy manufacturing, which is currently limited by high costs. By establishing a world-leading facility at Melbourn Science Park, Cellular Origins can leverage its automated platform to reduce manufacturing costs and increase the accessibility of transformative cell therapies. The location within the UK's R&D 'Golden Triangle' provides access to world-class research and talent, supporting innovation and growth. This expansion aligns with Cellular Origins' ambition to scale cell therapy manufacturing to meet growing patient demand, potentially revolutionizing the industry and improving patient outcomes.
What's Next?
Cellular Origins plans to expand its workforce and enhance collaboration with global partners as part of its growth strategy. The company will focus on developing its automated manufacturing platform, Constellation, to deliver commercial-scale cell therapy systems. The new headquarters at Melbourn Science Park will serve as a hub for innovation, providing access to research and talent. Cellular Origins aims to create scalable programs that can expand over time, supporting the industrialization of cell therapy manufacturing. The partnership with Bruntwood SciTech reflects a commitment to fostering innovation-led businesses and supporting their growth in the UK.
